Fig. 5. Pyruvate-to-lactate conversion flux varies in PDXs, which were resistant and sensitive to FX11 treatment.

Representative dynamic ¹³C MR spectra acquired from FX11 resistant JH033 (TP53 wild type) and FX11 sensitive P253 tumor, a TP53 mutant PDX. Spectra captured prior to D7 FX11 treatment of JH033 and P253 are shown in A and B, and C and D, respectively. Sequential spectra were acquired from a 5-mm tumor slice over 150 seconds after i.v. injection of hyperpolarized [1-¹³C] pyruvate as described in materials and methods. Tumor lactate and pyruvate peak intensities with time after i.v. injection of hyperpolarized ¹³C pyruvate is shown prior to FX11 treatment (E and G) and D7 FX11 treatment (F and H) in JH033 and P253, respectively. Representative anatomical T₂-weighted axial MR images containing slice ROI (red box) are shown in inset.